Top news
News

search

topic
content
News
Position : Home Page >> News
Rezvilutamide Tablets Approved with Condition for Marketing
    Pubtime: 2022-09-20

  Recently, the Rezvilutamide Tablet (Chinese trade name: 艾瑞恩) of Jiangsu Hengrui Pharmaceuticals Co., Ltd is approved with condition for marketing through the priority review and approval procedure by NMPA in China. This drug is indicated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) patients with high tumor burden.

  Rezvilutamide is an androgen receptor (AR) inhibitor that competitively inhibits androgen binding to AR, thereby inhibiting AR nuclear translocation and DNA binding, and reducing AR-mediated gene transcription. This product provides a new treatment option available for patients with prostate cancer.

Produced By CMS 网站群内容管理系统 publishdate:2025/03/19 21:46:16